Leukocyte immunoglobulin‐like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond
Abstract Leukocyte immunoglobulin‐like receptor B4 (LILRB4) significantly impacts immune regulation and the pathogenesis and progression of various cancers. This review discusses LILRB4's structural attributes, expression patterns in immune cells, and molecular mechanisms in modulating immune r...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Cancer Innovation |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cai2.153 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846173711640559616 |
|---|---|
| author | Qi Liu Yuyang Liu Zhanyu Yang |
| author_facet | Qi Liu Yuyang Liu Zhanyu Yang |
| author_sort | Qi Liu |
| collection | DOAJ |
| description | Abstract Leukocyte immunoglobulin‐like receptor B4 (LILRB4) significantly impacts immune regulation and the pathogenesis and progression of various cancers. This review discusses LILRB4's structural attributes, expression patterns in immune cells, and molecular mechanisms in modulating immune responses. We describe the influence of LILRB4 on T cells, dendritic cells, NK cells, and macrophages, and its dual role in stimulating and suppressing immune activities. The review discusses the current research on LILRB4's involvement in acute myeloid leukemia, chronic lymphocytic leukemia, and solid tumors, such as colorectal cancer, pancreatic cancer, non‐small cell lung cancer, hepatocellular carcinoma, and extramedullary multiple myeloma. The review also describes LILRB4's role in autoimmune disorders, infectious diseases, and other conditions. We evaluate the recent advancements in targeting LILRB4 using monoclonal antibodies and peptide inhibitors and their therapeutic potential in cancer treatment. Together, these studies underscore the need for further research on LILRB4's interactions in the tumor microenvironment and highlight its importance as a therapeutic target in oncology and for future clinical innovations. |
| format | Article |
| id | doaj-art-e9532c5719b24ad2b8621bb91c921b9e |
| institution | Kabale University |
| issn | 2770-9191 2770-9183 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Innovation |
| spelling | doaj-art-e9532c5719b24ad2b8621bb91c921b9e2024-11-08T13:38:27ZengWileyCancer Innovation2770-91912770-91832024-12-0136n/an/a10.1002/cai2.153Leukocyte immunoglobulin‐like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyondQi Liu0Yuyang Liu1Zhanyu Yang2Faculty of Hepato‐Pancreato‐Biliary Surgery, The First Medical Center Chinese People's Liberation Army General Hospital Beijing ChinaDepartment of Neurosurgery 920th Hospital of Joint Logistics Support Force Kunming Yunnan ChinaFaculty of Hepato‐Pancreato‐Biliary Surgery, The First Medical Center Chinese People's Liberation Army General Hospital Beijing ChinaAbstract Leukocyte immunoglobulin‐like receptor B4 (LILRB4) significantly impacts immune regulation and the pathogenesis and progression of various cancers. This review discusses LILRB4's structural attributes, expression patterns in immune cells, and molecular mechanisms in modulating immune responses. We describe the influence of LILRB4 on T cells, dendritic cells, NK cells, and macrophages, and its dual role in stimulating and suppressing immune activities. The review discusses the current research on LILRB4's involvement in acute myeloid leukemia, chronic lymphocytic leukemia, and solid tumors, such as colorectal cancer, pancreatic cancer, non‐small cell lung cancer, hepatocellular carcinoma, and extramedullary multiple myeloma. The review also describes LILRB4's role in autoimmune disorders, infectious diseases, and other conditions. We evaluate the recent advancements in targeting LILRB4 using monoclonal antibodies and peptide inhibitors and their therapeutic potential in cancer treatment. Together, these studies underscore the need for further research on LILRB4's interactions in the tumor microenvironment and highlight its importance as a therapeutic target in oncology and for future clinical innovations.https://doi.org/10.1002/cai2.153cancer therapyimmune checkpointimmunotherapyleukocyte immunoglobulin‐like receptor B4monoclonal antibodies |
| spellingShingle | Qi Liu Yuyang Liu Zhanyu Yang Leukocyte immunoglobulin‐like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond Cancer Innovation cancer therapy immune checkpoint immunotherapy leukocyte immunoglobulin‐like receptor B4 monoclonal antibodies |
| title | Leukocyte immunoglobulin‐like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond |
| title_full | Leukocyte immunoglobulin‐like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond |
| title_fullStr | Leukocyte immunoglobulin‐like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond |
| title_full_unstemmed | Leukocyte immunoglobulin‐like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond |
| title_short | Leukocyte immunoglobulin‐like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond |
| title_sort | leukocyte immunoglobulin like receptor b4 a keystone in immune modulation and therapeutic target in cancer and beyond |
| topic | cancer therapy immune checkpoint immunotherapy leukocyte immunoglobulin‐like receptor B4 monoclonal antibodies |
| url | https://doi.org/10.1002/cai2.153 |
| work_keys_str_mv | AT qiliu leukocyteimmunoglobulinlikereceptorb4akeystoneinimmunemodulationandtherapeutictargetincancerandbeyond AT yuyangliu leukocyteimmunoglobulinlikereceptorb4akeystoneinimmunemodulationandtherapeutictargetincancerandbeyond AT zhanyuyang leukocyteimmunoglobulinlikereceptorb4akeystoneinimmunemodulationandtherapeutictargetincancerandbeyond |